Post Profile






Anthem says will not cover Sarepta's approved Duchenne drug

(Reuters) - Health insurer Anthem Inc said it will not cover Sarepta Therapeutics Inc's drug to treat the rare condition of Duchenne muscular dystrophy (DMD), calling it "investigational and not medically necessary."
read more

share

Related Posts


Sarepta Therapeutics Inc (SRPT) Moves Ahead With Seeking Eteplirsen Approval: Hip, Hip, Uh-Oh?

Business & Finance / Investing : Insider Monkey

Investors wondered for months if Sarepta Therapeutics Inc (NASDAQ:SRPT) would pursue accelerated approval for Duchenne muscular dystrophy, or DMD, drug eteplirsen. Sarepta gave its answer to those questions before the market opened ...

Sarepta Therapeutics Inc (SRPT), GlaxoSmithKline plc (ADR) (GSK): An Edge Emerges in the Race to Treat Muscular Dystrophy

Business & Finance / Investing : Insider Monkey

In a previous article, I speculated on the race to develop a Duchenne muscular dystrophy, or DMD, drug and who might win it. It seems now that Sarepta Therapeutics Inc (NASDAQ:SRPT) has moved a step ahead after disappointing mid-sta...

Sarepta Wins FDA Nod For Embattled DMD Drug -- But With A Catch

Business & Finance : Forbes: Business

Just five days after its main nemesis at the FDA departed the agency, Sarepta Therapeutics has won a long-sought-after approval for eteplirsen, its drug to treat Duchenne muscular dystrophy (DMD). But the company's battle isn't over...

Anthem Says It Won't Cover Sarepta's Muscular Dystrophy Drug

Business & Finance : Forbes: Business

Anthem, one of the nation's largest health insurers, said it won’t cover the expensive biotech drug Duchene for muscular dystrophy, saying its “investigational and not medically necessary."

Summit and Sarepta to collaborate on muscular dystrophy drug

Health : Reuters: Health

(Reuters) - Drugmaker Sarepta Therapeutics Inc has entered into an exclusive license agreement with Britain's Summit Therapeutics Plc to develop drugs to treat Duchenne muscular dystrophy (DMD), the companies said on Tuesday.

Comments


Copyright © 2016 Regator, LLC